Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tidbits From The SG Cowen Health Care Conference

Executive Summary

King/Elan deal in jeopardy?: King is "evaluating the effect" that FTC's investigation into Elan's Skelaxin will have on its proposed acquisition of Elan's primary care business. King is "evaluating what our rights are under our contract," company says at SG Cowen March 19. FTC opened an investigation into Elan's "Orange Book" patent listings for the muscle relaxant (1"The Pink Sheet" March 17, In Brief). King reiterated that it will not purchase the sleep agent Sonata as a stand-alone product. "The transaction is not structured that way." The $850 mil. deal, which has a deadline of July 31, would add 400 sales reps to King's 800-person force ("The Pink Sheet" Feb. 3, p. 29)...

You may also be interested in...



Abbott Sees Atrasentan Market Opportunity In Less Advanced Prostate Cancer

Abbott sees a market opportunity for atrasentan in prostate cancer patients with less advanced disease based on the company's initial subset analysis of an unfavorable Phase III study for the endothelin-1 receptor antagonist

Abbott Sees Atrasentan Market Opportunity In Less Advanced Prostate Cancer

Abbott sees a market opportunity for atrasentan in prostate cancer patients with less advanced disease based on the company's initial subset analysis of an unfavorable Phase III study for the endothelin-1 receptor antagonist

King Acquisition Strategy Will Be Driven By Late-Stage Product Deals

King Pharmaceuticals is shifting its acquisition strategy to either purchasing or in-licensing late-stage drugs rather than already-marketed products, the company told investors during a quarterly conference call May 6

Related Content

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel